Sensei Biotherapeutics (NASDAQ:SNSE) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.22) by 22.73 percent. This is a 15.62 percent increase over losses of $(0.32) per share from the same period last year.